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Abstract 
Hetrombopag as the derivative of ethylidene hydrazine carboxamide was recently developed into a novel patented 
non-peptide thrombopoietin mimetic and thrombopoietin receptor agonist to treat idiopathic thrombocytopenic 
purpura. To study the pharmacokinetics of hetrombopag, a highly sensitive, rapid and reliable liquid chromatography-
tandem mass spectrometry (LC–MS/MS) method was developed and validated for determination of hetrombopag 
in rat plasma. After protein precipitation extraction, the chromatography separation of analyte and internal standard 
named eltrombopag as an marketed analog of hetrombopag was performed on an Synergi Polar-RP column at the 
flow rate of 0.5 mL/min, and the determination was conducted on an API4000 triple quadrupole mass spectrometry 
in the multiple reaction monitoring mode using the respective [M+H]+ ions m/z 459.2 → 200.9 for hetrombopag 
and m/z 443.2 → 229.0 for IS. The lower limit of quantification was established to be 1 ng/mL, and the linear scope 
of standard curve was 1–1000 ng/mL. Both the precision (RSD%) and accuracy (RE%) were within the acceptable crite-
rion of below 15 %. The validated method was successfully applied to quantify hetrombopag in the rat plasma and 
investigate the pharmacokinetics.
Keywords: Hetrombopag, Pharmacokinetics, Idiopathic thrombocytopenic purpura, LC–MS/MS
© 2015 Chen et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Background
Idiopathic thrombocytopenic purpura (ITP) involved in 
anti-platelet antibody mediated platelet destruction and 
reduced platelet production is a common autoimmune 
disease in hematology department (Heitink-Pollé et  al. 
2014; Lo and Deane 2014). ITP usually indicating the 
persistently low platelet counts less than 20,000 mm3 are 
associated with an increased risk of serious bleeding such 
as intracranial hemorrhage (Aledort et al. 2004). One of 
the ITP etiology is that there is no enough thrombopoi-
etin to stimulate platelet production (Kuter 2013). So 
improving the thrombopoietin concentration level will 
be great benefit of treating ITP (Imbach and Crowther 
2011). Eltrombapag (SB-497115) as thrombopoietin stim-
ulant agent has been approved by FDA and demonstrated 
that it can significantly increase the platelet counts in 





furan-2-carboxylic acid), the analog of eltrombopag, was 
developed by Jiangsu Hengrui pharmaceutical company 
limited as a novel patented thrombopoietin receptor ago-
nist to treat idiopathic thrombocytopenia (Tang et  al. 
2009). However, some methods have been published for 
quantification of eltrombopag (Maddela et al. 2014; Deng 
et  al. 2011), there is no reported analytical methods for 
quantification of hetrombopag. Due to its different struc-
tural characteristic and corresponding physicochemi-
cal properties of the hetrombopag, it remains to be a 
challenge to develop a sensitive and selective method 
for determination of the plasma concentration of this 
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innovative chemical entity. Compared with conven-
tional HPLC methods, the LC–MS/MS method is more 
sensitive, rapid and applicable (Li et al. 2011). Thus, it is 
necessary to establish a suitable LC–MS/MS method to 
accurately quantify the plasma concentration of hetrom-
bopag. In this study, it is the first time to develop and val-
idate a sensitive, specific and reproducible LC–MS/MS 
method for quantification of hetrombopag in rat plasma. 
The protein precipitation was used to prepare samples 
and the eltrombopag was adopted as the internal stand-
ard (IS). This analytical method was successfully applied 




Hetrombopag (98.75  %purity), eltrombopag (internal 
standard (IS) for hetrombopag, 99.29  % purity) were 
supplied by Jiangsu Hengrui pharmaceutical Co. Ltd 
(Jangsu, China) Methanol, acetonitrile, dimethyl sulfox-
ide (DMSO), formic acid of HPLC grade were purchased 
from Merck (Darmstadt, Germany). High-purity water 
(18.3 MΩ) was purified by a Millipore Milli-Q Gradient 
Water Purification System (Millipore, Bedford, USA).
Instrumentation and conditions
Liquid chromatography
Chromatographic analysis was performed using a Shi-
madzu LC-20AD HPLC system (Shimadzu, Kyoto, Japan) 
and equipped with the CTC HTS-XT PAL Leap autosa-
mpler (Carrboro, NC, USA). The separation column was 
Synergi Polar-RP column (50 × 2.0 mm, 4 μm, Phenom-
enex, Torrance, CA). Mobile phase A was water with 0.1 % 
v/v formic acid, 31 % v/v acetonitrile, 31 % v/v methanol 
and mobile phase B was methanol with 0.5 % v/v formic 
acid at a flow rate of 0.5 ml/min according to the following 
linear gradient: 0–2.50 min, 55 % B; 2.51–3.50 min, 95 % 
B; 3.51–4.00 min, 55 % B. The injection volume was 20 μL.
Mass spectrometry
Samples were analyzed with an API4000 mass spec-
trometer (AB Sciex, Toronto, Canada) equipped with an 
ESI source operating in the positive ion (ESI+) mode. 
The software used for controlling this equipment and 
analyzing the data was Analyst Version 1.6.1 (AB Sciex, 
Toronto, Canada). Samples were detected in the multiple 
reaction monitor (MRM) mode. The mass transitions of 
the compounds were: hetrombopag, m/z 459.2 → 200.9 
and eltrombopag (IS), m/z 443.2 → 229.0.
The primary parameters of the mass spectrometer 
were described as follows: ion spray voltage, 4.5 kV; tem-
perature, 500  °C; curtain gas, 30  psi; gas 1 (nebulizer 
gas) 50  psi; gas 2 (heater gas) 60  psi; collision activate 
dissociation (CAD) gas 10 psi; collision cell exit poten-
tial (CXP), 14  V; declustering potentials (DP): 74  V for 
hetrombopag, 81 V for IS; collision energies (CE): 41 eV 
for hetrombopag, 28 eV for IS; dwell time, 150 ms. The 
gases used were nitrogen.
Preparation of standard solutions and quality control (QC) 
samples
The appropriate amount of hetrombopag was accu-
rately and independently weighted in two replicates and 
dissolved with a small amount of dimethyl sulfoxide 
(DMSO) firstly, and then dissolved in methanol to pro-
duce the standard stock solutions at the concentration of 
1  mg/mL, respectively. The final DMSO concentration 
was around 0.1  %. One of standard stock solutions was 
prepared for standard solutions, and the other was pre-
pared for QC samples. A serial of hetrombopag standard 
working solutions were produced by diluting standard 
solutions with methanol–water (v/v, 50:50) to obtain the 
desired concentration. The calibration standards were 
prepared by spiking 50  μL standard working solutions 
to 50 μL drug-free rat plasma at the concentrations of 1, 
3, 10, 30, 100, 250, 500, 750, 1000 ng/mL. The QC sam-
ples were produced by diluting standard solutions with 
drug-free rat plasma at the concentrations of 2, 150, 600, 
800 ng/mL. The similar stock solution of IS was diluted 
at the concentration of 700  ng/mL working solution. 
These solutions were all stored at 4 °C and then brought 
to room temperature before use.
Sample preparation
All the frozen rat plasma samples were thawed at room 
temperature and vortexed thoroughly. A 50 μL aliquot of 
IS and 50 μL methanol–water (v/v, 50:50) were added to 
50 μL plasma sample with a 96-well plate. Then 200 μL 
methanol were added to the sample for precipitation. 
The sample was vortex-mixed for 15  min, and centri-
fuged 3220g for 20  min under 15  °C. The supernatant 
(20 μL) was then injected into the LC–MS/MS system for 
analysis.
Method validation
Method validation was performed based on the US Food 
and Drug Administration (FDA) guideline for industry 
bioanalytical method validation (FDA 2001) and Euro-
pean Medicines Agency (EMA) guideline (EMA 2009). 
The validation was assessed included specificity, linearity, 
inter- and intra-precision and accuracy, extraction recov-
ery, matrix effect and stability.
Specificity
The selectivity was evaluated by analyzing 6 drug-free 
plasma samples and 12 spiked plasma samples at the 
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lower limit of quantification (LLOQ) level from six dif-
ferent rat plasma sources. The MRM chromatograms of 
the blank plasma samples were compared with the cor-
responding spiked plasma samples with analyte and IS. 
The peak areas of the endogenous compounds co-eluted 
with the analytes should be ≤20 % of the peak area of the 
LLOQ standard.
Linearity and LLOQ
The linearity was estimated by assaying calibration curves 
in rat plasma in duplication on three consecutive days. 
The calibration curves were fitted by a weighted (1/x2) 
least squares linear regression method and its acceptable 
criterion was that correlation coefficient (r) was ≥0.995.
The LLOQ defined as the lowest concentration of the 
calibration curve was determined in six replicates in 
three validation runs. Compared with the nominal con-
centration, the accuracy was within ±20 % and the preci-
sion was ≤20 %.
Accuracy and precision
Accuracy and precision were evaluated by determining 
the concentrations of QC samples at four levels using 
six replicates on three validation runs. The relative error 
(RE%) was used to assessing the accuracy and relative 
standard deviation (RSD%) was used to assessing the 
precision. The acceptable criterion of the inter-day and 
intra-day precision was less than 15 %, and the accuracy 
was within ±15 %.
Dilution reliability
A sample was spiked at 8000 ng/mL for hetrombopag and 
diluted by blank plasma to 10-fold, 25-fold and 50-fold in 
six replicates, respectively. The concentrations of diluted 
samples were all over the calibration curve. Compared 
with the concentration of samples before dilution, the 
accuracy should be between 85 and 115  %, and relative 
error should be less than 15 %.
Extraction recovery and matrix effect
Extraction recovery was assessed at three concentration 
levels by comparing peak areas of analyte and IS in six 
replicate QC samples with those of post-extracted blank 
plasma spiked at corresponding concentrations. The 
post-extracted samples represented 100 % recovery.
Matrix effect (ME) was conducted at low and high con-
centration levels by comparing peak areas of analyte and 
IS in triplicate with those at the same concentration solu-
tions. The drug-free rat plasma from six different donors 
were precipitated and then spiked with analyte and IS, 
the peak areas of which was defined as A. Those of the 
water-substituted samples at same concentrations were 
defined as B. The ratio (A/B  ×  100  %) was defined as 
matrix factor (MF) for investigating ME. The RSD% of IS-
normalized matrix factors should be less than 15 %.
Stability
The stability of hetrombopag in rat plasma was assessed 
by determining the low QC and high QC samples in trip-
licate under different conditions. The short-term stability 
was determined via analyzing the QC samples exposed 
to the room temperature for 4 h. The samples after pro-
tein precipitation were exposed to the autosampler for 
24 h in room temperature to estimate the post-prepara-
tive stability. Freeze–thaw stability was evaluated after 
3 freeze–thaw cycle of the QC samples from −80  °C to 
ambient temperature on consecutive days, and the long-
term stability was assessed at the −80 °C for 45 days. The 
acceptable criteria of the stability was within ±15  % of 
the accuracy.
Pharmaceutical study
The validated analytical method was successfully applied 
to pharmaceutical study of hetrombopag in rats (9 
females, 9 males) purchased form Guangdong Province 
Experimental Animal Center. The procedure about this 
animal experiment was approved by the animal ethics 
committee of Guangdong Pharmaceutical University. 
Hetrombopag (10, 30, 60 mg/kg) was oral administrated 
by intragastric administration and blood samples were 
collected into EDTA.2K tubes from the retrobulbar 
venous plexus at before dosing and at 0.25, 0.5, 1, 2, 4, 
6, 8, 12, 24, 48 h after dosing. The plasma samples were 
separated through centrifuge immediately and stored 
at −80  °C until analysis. Software Kinetica 4.4.1 (USA, 
Thermo Electron Corporation Company) was adopted 
for the pharmacokintic analysis.
Results and discussion
Optimization of mass spectrometric condition
The mass spectrometry parameters were optimized 
by directly infusing the 1  μg/mL standard solution of 
hetrombopag and eltrombopag into the mass spec-
trometry, respectively. Taking the signal response into 
consideration, the positive mode was chosen to quan-
tify hetrombopag. Under the positive ESI conditions, 
hetrombopag and eltrombopag produced predominantly 
protonated molecule [M+H]+ at m/z 459.2 and m/z 
443.2 respectively in Q1 full scan mass spectra. The cor-
responding product ion mass spectra were showed in 
Fig. 1, where [M+H]+ of each compound was selected as 
precursor ion. Hetrobopag produced primarily fragment 
ions at m/z 219.0 and 200.9, and we chosen MRM transi-
tion m/z 459.2 → 200.9 for quantification analysis due to 
its more stable and less disturbed presence than the m/z 
459.2 →  219.0. Similarly, the most abundant and stable 
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fragment ions at m/z 443.2 → 229.0 was selected as the 
transition for IS.
Chromatography
In order to obtain a suitable chromatography, a lot of 
commercially available column were assessed including 
Synergi hydro-RP C18, Gemini C18, Kinetex C18 and 
Synergi Polar-RP. In respect of the peak shape, retention 
time, sensitivity, carry-over and baseline noise for analyte 
and IS, the Synergi Polar-RP column (50 × 2.0 mm, 4 μm) 
column was found to be optimal, which exhibited good 
peak shape and retention time. As the hetrombopag was 
hard to be eluted and the carry-over effect was observed, 
the composition of mobile phases was also investigated. 
As a consequence, methanol–acetonitrile with formic 
acid was optimal mobile phase. Using the gradient elu-
tion, the analytical run time was 4  min, and the reten-




The results of typical chromatograph shown in Figs. 2, 3 
indicated that the response of endogenous compounds 
co-eluted with analyte was within 20  % of the LLOQ 
standard, which demonstrated that the endogenous com-
pounds had no effect on the quantification of hetrom-
bopag under current conditions.
Linearity and LLOQ
The calibration curve of concentration of hetrom-
bopag over the ranges of 1–1000  ng/mL was estab-
lished by weighted (1/x2) linear regression analysis, 
and the coefficient correlation (R) was ≥0.995. The 
typical equation of hetrombopag calibration curve was 
y =  0.00204x +  0.0000939 (r =  0.9987), where y repre-
sents the ratio of the peak area of the analyte to that of IS, 
and x represents the plasma concentration.
The LLOQ of hetrombopag in rat plasma was 1  ng/
mL, the sensitivity was enough to determine the plasma 
concentration and investigate the pharmacokinetics of 
hetrombopag in rat. The mean inter-and intra-assay pre-
cision (RSD%) at LLOQ concentration level were 11.3 
and 5.6  %, respectively, with relative error 5.4  %, which 
was described in Table 1.
Precision and accuracy
The inter- and intra-assay precision and accuracy values 
of QC samples were depicted in Table  1. The values of 
inter- and intra-assay mean precision were less than 9.7 
and 8.7 %, respectively, and the mean values of accuracy 
were between −3.8 and 2.5  %, which revealed that the 
current method was reliable, accurate and reproducible.
Dilution reliability
The results of dilution factor (DF) showed in Table  2, 
and the values of precision and accuracy were all in 
the acceptable ranges, which were ≤2.1 and ≤11.7  %, 
respectively.
Matrix effect and extraction recovery
The matrix factors from six different lots of blank plasma 
ranged from 67.6 to 91.8 % for analyte and IS. The RSD 
of the inter-subject variability of the IS-normalized MF 
was less than 13.7 %. The results indicated that the ion-
enhancement or suppression from rat plasma matrix 
were negligible under current method.
The mean extraction recoveries of hetrombopag from 
three different QC levels were 88.1, 85.0, 91.0 %, respec-
tively. The mean extraction recovery of IS was 75.2  %. 
The results demonstrated that the extraction process is 
efficient.
Stability
The detailed results of stability showed in Table  3. The 
results showed that the analyte of samples was sta-
ble after exposed to the room temperature for 4  h, 3 
Fig. 1 Production mass spectra of [M+H]+ ion of a hetrombopag, 
and b eltrombopag
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freeze–thaw cycle −80  °C to ambient temperature on 
consecutive days and stored at −80  °C for 45  days. The 
samples after extraction stored at the autosampler for 
24 h in room temperature remained to be stable.
Pharmacokinetic study
The assay depicted in this study was successfully applied 
to investigate the pharmacokinetic profiles of hetrom-
bopag in rats following intragastrical administration of 
10, 30, 60  mg/kg hetrombopag ethanolamine tablets. 
Figure  4 demonstrated the plasma concentration–time 
curves, and the main pharmacokinetic parameters for 
hetrombopag were presented in Table  4. The t1/2 val-
ues for hetrombopag was approximately 8–9  h, and the 
Cmax (µg/mL) were 13.1 ± 6.0, 21.6 ± 12.3, 34.6 ± 11.9 
after intragastrical administration of 10, 30, 60  mg/kg 
hetrombopag, respectively. To our knowledge, this is the 
first time to report the pharmacokinetics parameter of 
hetrombopag analogs in rats.
Conclusion
A highly selective LC–MS/MS method was successfully 
developed and validated for determination of hetrom-
bopag in rat plasma for the first time. The analytical time 
of this method was 4  min, which was more rapid than 
conventional HPLC method, and a highly sensitive was 
observed in this method (LLOQ for hetrombopag was 
1 ng/mL). A simple and quick protein precipitation was 
used to extract the samples prior to LC–MS/MS analy-
sis. The method exhibited good precision, accuracy and 
wide linear concentration range. Hence, the current 
method could be suitable for providing sufficient sup-
port for further preclinical study in pharmacokinetics 
investigation.
Fig. 2 Typical chromatograms of hetrombopag and its corresponding internal standard in rat plasma. a double blank plasma (drug and IS free); b 
blank plasma (drug free and spiked with 700 ng/mL IS)
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Fig. 3 Typical chromatograms of hetrombopag and its corresponding internal standard in rat plasma. a LLOQ of hetrombopag in rat plasma 
(spiked with 1 ng/mL hetrombopag and 700 ng/mL combined IS; b plasma sample 0.25 h after intragastric administration of 60 mg/kg hetrom-
bopag ethanolamine tablets
Table 1 Precision and  accuracy data for  hetrombopag 
in rat plasma (3 days with 6 replicates per day)
Sample name Concentration (ng/mL) RSD (%) RE (%)
Nominal Calculated Intra-run Inter-run
LLOQ 1.0 1.1 11.3 5.6 5.4
QC4 2.0 2.1 9.7 3.9 2.5
QC3 150.0 151.5 2.6 4.1 1.0
QC2 600.0 605.2 2.7 2.5 0.9
QC1 800.0 770.0 2.7 8.7 −3.8
Table 2 Dilution factor (DF) for hetrombopag (n = 6)
Sample name Concentration(ng/mL) RSD (%) RE (%)
Nominal Calculated
DF 50-fold 160.0 178.7 2.1 11.7
DF 25-fold 320.0 326.8 1.4 2.1
DF 10-fold 800.0 811.5 1.5 1.4
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Storage conditions Concentration (ng/mL)RSD (%) RE (%)
Nominal Calculated
Long-term (−80 ℃ 45 days) 2 2.02 4.5 1.2
800 700 2.6 −12.5
Short-term (room temperature 
4 h)
2 2.12 5.2 5.8
800 713 2.9 −10.9
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Fig. 4 Mean drug plasma concentration–time curve of hetrom-
bopag from 18 rats (three levels doses) after intragastric administra-
tion
Table 4 The main pharmacokinetic parameters 
for hetrobopag after  intragastric administration of 10, 30 
and 60 mg/kg to rat, respectively (mean ± SD, n = 6)
Parameters 10 mg/kg 30 mg/kg 60 mg/kg
Cmax (µg/mL) 13.1 ± 6 21.6 ± 12.3 34.6 ± 11.9
Tmax (h) 0.7 ± 0.26 1.67 ± 0.52 2.58 ± 2.06
AUC0–48 h (µg h/mL) 46.2 ± 31 127.7 ± 70.8 306.6 ± 94.6
AUC0–∞ (µg h/mL) 46.7 ± 31.3 129.8 ± 72.8 312.8 ± 98.8
MRT (h) 6.5 ± 0.7 8.4 ± 1.7 105 ± 1.3
t1/2 (h) 8.5 ± 1.1 8.4 ± 1.1 8.8 ± 1.1
